AZN
Price
$72.60
Change
-$0.90 (-1.22%)
Updated
Apr 1 closing price
Capitalization
208.98B
27 days until earnings call
GSK
Price
$37.88
Change
-$0.86 (-2.22%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
88.13B
28 days until earnings call
Ad is loading...

AZN vs GSK

Header iconAZN vs GSK Comparison
Open Charts AZN vs GSKBanner chart's image
AstraZeneca
Price$72.60
Change-$0.90 (-1.22%)
Volume$4.73M
Capitalization208.98B
GSK
Price$37.88
Change-$0.86 (-2.22%)
Volume$27.01K
Capitalization88.13B
AZN vs GSK Comparison Chart
Loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AZN vs. GSK commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a StrongBuy and GSK is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (AZN: $73.50 vs. GSK: $38.74)
Brand notoriety: AZN: Notable vs. GSK: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 70% vs. GSK: 102%
Market capitalization -- AZN: $208.98B vs. GSK: $88.13B
AZN [@Pharmaceuticals: Major] is valued at $208.98B. GSK’s [@Pharmaceuticals: Major] market capitalization is $88.13B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 2 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • AZN’s FA Score: 2 green, 3 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, GSK is a better buy in the long-term than AZN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 4 TA indicator(s) are bullish while GSK’s TA Score has 3 bullish TA indicator(s).

  • AZN’s TA Score: 4 bullish, 4 bearish.
  • GSK’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AZN is a better buy in the short-term than GSK.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а -0.80% price change this week, while GSK (@Pharmaceuticals: Major) price change was +0.44% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.86%. For the same industry, the average monthly price growth was -1.23%, and the average quarterly price growth was -6.74%.

Reported Earning Dates

AZN is expected to report earnings on Apr 29, 2025.

GSK is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.86% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AZN($209B) has a higher market cap than GSK($88.1B). AZN has higher P/E ratio than GSK: AZN (35.30) vs GSK (14.01). GSK YTD gains are higher at: 15.803 vs. AZN (13.782). AZN has higher annual earnings (EBITDA): 13.4B vs. GSK (9.08B). AZN has more cash in the bank: 5.86B vs. GSK (4.99B). GSK has less debt than AZN: GSK (18B) vs AZN (28.6B). AZN has higher revenues than GSK: AZN (45.8B) vs GSK (30.3B).
AZNGSKAZN / GSK
Capitalization209B88.1B237%
EBITDA13.4B9.08B148%
Gain YTD13.78215.80387%
P/E Ratio35.3014.01252%
Revenue45.8B30.3B151%
Total Cash5.86B4.99B117%
Total Debt28.6B18B159%
FUNDAMENTALS RATINGS
AZN vs GSK: Fundamental Ratings
AZN
GSK
OUTLOOK RATING
1..100
7586
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
10
Undervalued
PROFIT vs RISK RATING
1..100
2769
SMR RATING
1..100
5148
PRICE GROWTH RATING
1..100
4948
P/E GROWTH RATING
1..100
549
SEASONALITY SCORE
1..100
9550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (10) in the Pharmaceuticals Major industry is in the same range as AZN (25). This means that GSK’s stock grew similarly to AZN’s over the last 12 months.

AZN's Profit vs Risk Rating (27) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (69). This means that AZN’s stock grew somewhat faster than GSK’s over the last 12 months.

GSK's SMR Rating (48) in the Pharmaceuticals Major industry is in the same range as AZN (51). This means that GSK’s stock grew similarly to AZN’s over the last 12 months.

GSK's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as AZN (49). This means that GSK’s stock grew similarly to AZN’s over the last 12 months.

GSK's P/E Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZN (54). This means that GSK’s stock grew somewhat faster than AZN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNGSK
RSI
ODDS (%)
Bearish Trend 2 days ago
54%
Bearish Trend 2 days ago
35%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
55%
Momentum
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
44%
MACD
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
49%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
44%
Bullish Trend 2 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
43%
Bullish Trend 2 days ago
50%
Advances
ODDS (%)
Bullish Trend 5 days ago
56%
Bullish Trend 5 days ago
54%
Declines
ODDS (%)
Bearish Trend 7 days ago
43%
Bearish Trend 9 days ago
52%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
53%
Bearish Trend 2 days ago
50%
Aroon
ODDS (%)
Bullish Trend 2 days ago
45%
Bullish Trend 2 days ago
45%
View a ticker or compare two or three
Ad is loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NGD3.710.11
+3.06%
New Gold
ABEV2.330.05
+2.19%
Ambev SA
PKE13.45-0.04
-0.30%
Park Aerospace Corp
SNT3.46-0.02
-0.57%
Senstar Technologies Corp
VMI285.37-4.19
-1.45%
Valmont Industries

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
N/A
NVS - GSK
49%
Loosely correlated
-0.97%
PFE - GSK
47%
Loosely correlated
+0.52%
SNY - GSK
40%
Loosely correlated
-0.64%
JNJ - GSK
40%
Loosely correlated
+1.30%
AZN - GSK
38%
Loosely correlated
-0.39%
More